ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 2992

Are Specific Vascular Symptoms in Takayasu’s Arteritis Reflective of Vascular Inflammation, Vascular Damage, or Both?

Despina Michailidou1, Joel S. Rosenblum1, Mark A. Ahlman2, Jamie Marco3 and Peter C. Grayson4, 1NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, 2Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, 3Radiology and Imaging Sciences National Institutes of Health, Bethesda, MD, 4National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Disease Activity and Takayasu.s arteritis

Session Information

Date: Wednesday, October 24, 2018

Title: 6W025 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os III: Clinical Subtype & Outcome(2988–2993)

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose:

Patients with Takayasu’s arteritis (TAK) can experience symptoms due to vascular inflammation or vascular damage. The study objective was to investigate whether specific vascular symptoms are more closely associated with vascular disease activity measured by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) or vascular damage assessed by magnetic resonance angiography (MRA).

Methods:

Patients with TAK were recruited into a prospective observational cohort. Participants underwent clinical assessment and standardized imaging assessment (FDG-PET and MRA) within a 24-hour period, blinded to each other. Vascular disease activity was defined as arterial FDG uptake > liver by visual assessment. Vascular damage was defined as either stenosis, occlusion, or aneurysm in specific arterial territories on MRA. Clinical symptoms present on the day of evaluation (carotidynia; frontal headache; arm claudication) were compared to imaging findings in corresponding arterial territories. Generalized symptoms (headache; dizziness; history of CNS event defined as TIA/stroke or syncope) were studied in association with the number of affected neck vessels by MRA. Performance characteristics were calculated and the association between clinical symptoms and imaging features was assessed by Fisher’s exact test.

Results:

51 participants contributed data from 92 study visits. For FDG-PET, the sensitivity (SN) of specific clinical symptoms ranged from 16% to 33% and specificity (SP) from 74% to 98%. For MRA the SN of the same symptoms ranged from 6% to 71% and SP from 79% to 100%. Details of specific associations are shown in the Table. Carotidynia was significantly associated with carotid activity by FDG-PET (p<0.01) but not carotid damage by MRA (p=0.18). Frontal headache was significantly associated with both carotid activity by FDG-PET (p<0.01) and carotid damage by MRA (p=0.04). Arm claudication was significantly associated with subclavian damage by MRA (p<0.01) but not subclavian activity by FDG-PET (p=0.47). Headache (p=0.02) and history of CNS events (p<0.01) was significantly associated with damage to ≥2 neck arteries, and dizziness (p<0.01) was associated with damage to ≥ 3 neck arteries.

Conclusion:

Absence of clinical symptoms does not rule out vascular abnormalities by FDG-PET or MRA, but presence of symptoms is often associated with imaging abnormalities. Certain features are more closely associated with FDG-PET activity while others are more closely linked to vascular damage. Complaints of headache, dizziness, and CNS events are associated with the burden of vascular pathology in the neck arteries. These findings have direct clinical implications and may inform the development of disease activity indices in TAK.

 

Table. Association of Clinical Symptoms with Imaging Findings in Takayasu’s Arteritis

 

Symptom

Arterial territory

Image Study

TN

TP

FN

FP

P value

Sensitivity (95% CI)

Specificity (95% CI)

Carotidynia

L carotid artery

R carotid artery

FDG-PET

122

8

17

5

<0.01

32%

(15-54%)

96%

(91-99%)

MRA

66

12

82

4

0.18

13%

(7-21%)

94%

(86-98%)

Frontal headache

L carotid artery

R carotid artery

FDG-PET

125

4

21

2

<0.01

16%

(5-36%)

98%

(94-100%)

MRA

70

6

88

0

0.04

6%

(2-13%)

100%

(95-100%)

Arm claudication

L subclavian artery

R subclavian artery

FDG-PET

95

8

16

34

0.47

33%

(16-55%)

74%

(65-81%)

MRA

67

38

49

8

<0.01

44%

(33-55%)

89%

(80-95%)

Any headache

≥2 vs <2 affected neck arteries (carotids, vertebrals)

MRA

45

12

12

12

0.02

50%

(29-71%)

79%

(66-89%)

History of CNS event

(TIA, stroke, or syncope)

≥2 vs <2 affected neck arteries (carotids, vertebrals)

MRA

45

17

7

12

<0.01

71%

(49-87%)

79%

(66-89%)

Dizziness

≥3 vs <3 affected neck arteries (carotids, vertebrals)

MRA

61

7

11

2

<0.01

39%

(17-64%)

97%

(89-100%)

TN = True Negative; TP = True Position; FN = False Negative; FP = False Position; CNS = Central Nervous System; TIA = Transient Ischemic Attack;

 


Disclosure: D. Michailidou, None; J. S. Rosenblum, None; M. A. Ahlman, None; J. Marco, None; P. C. Grayson, None.

To cite this abstract in AMA style:

Michailidou D, Rosenblum JS, Ahlman MA, Marco J, Grayson PC. Are Specific Vascular Symptoms in Takayasu’s Arteritis Reflective of Vascular Inflammation, Vascular Damage, or Both? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/are-specific-vascular-symptoms-in-takayasus-arteritis-reflective-of-vascular-inflammation-vascular-damage-or-both/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-specific-vascular-symptoms-in-takayasus-arteritis-reflective-of-vascular-inflammation-vascular-damage-or-both/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology